| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AVE Stock Overview
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries.
Avecho Biotechnology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.023 |
| 52 Week Low | AU$0.012 |
| Beta | 1.96 |
| 1 Month Change | 8.33% |
| 3 Month Change | -18.75% |
| 1 Year Change | -18.75% |
| 3 Year Change | 225.00% |
| 5 Year Change | -31.58% |
| Change since IPO | -97.29% |
Recent News & Updates
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Shareholder Returns
| AVE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 0.7% |
| 1Y | -18.8% | -11.0% | -8.5% |
Return vs Industry: AVE underperformed the Australian Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: AVE underperformed the Australian Market which returned -8.5% over the past year.
Price Volatility
| AVE volatility | |
|---|---|
| AVE Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 12.6% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in AU Market | 18.1% |
| 10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: AVE is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: AVE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Paul Gavin | https://avecho.com.au |
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company’s human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches.
Avecho Biotechnology Limited Fundamentals Summary
| AVE fundamental statistics | |
|---|---|
| Market Cap | AU$23.89m |
| Earnings (TTM) | -AU$3.42m |
| Revenue (TTM) | AU$793.60k |
30.2x
P/S Ratio-7.0x
P/E RatioIs AVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVE income statement (TTM) | |
|---|---|
| Revenue | AU$793.60k |
| Cost of Revenue | AU$285.66k |
| Gross Profit | AU$507.94k |
| Other Expenses | AU$3.92m |
| Earnings | -AU$3.42m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0019 |
| Gross Margin | 64.00% |
| Net Profit Margin | -430.46% |
| Debt/Equity Ratio | 0% |
How did AVE perform over the long term?
See historical performance and comparison